# 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne

> **NCT02524665** · PHASE4 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 20 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **OTHER:** MAXCLARITY II (2.5% BPO) Foam Cleanser
- **OTHER:** MAXCLARITY II (2.5% BPO) Foam Treatment
- **OTHER:** MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
- **OTHER:** MURAD Clarifying Cleanser (1.5% SA)
- **OTHER:** Exfoliating Acne Treatment Gel (1% SA)
- **OTHER:** Skin Perfecting Lotion

## Key facts

- **NCT ID:** NCT02524665
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02524665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02524665, "8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02524665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*